| Source: HalifaxProj(inhibit) CGL-CS |
| Type: |
| Phosphatidylinositol 3-kinase (PtdIns3K or PI3K) is a family of enzymes that play a crucial role in cell signaling pathways, particularly in the regulation of cell growth, survival, and metabolism. The PI3K pathway is one of the most frequently altered pathways in human cancer.
Inhibition of the PI3K pathway has been explored as a therapeutic strategy for cancer treatment. Several PI3K inhibitors have been developed and are currently being tested in clinical trials. These inhibitors can target specific components of the pathway, such as PI3K, AKT, or mTOR. Class I phosphoinositide 3-kinase (PI3K) Class III PtdIns3K In contrast to the class III PtdIns3K as a positive regulator of autophagy, class I PI3K-AKT signaling has an opposing effect on the initiation of autophagy. PI3K inhibitors include: -Idelalisib , Copanlisib, Alpelisib -LY294002? -Wortmannin: potent PI3K inhibitor, has some associated toxicity. -Quercetin: -Curcumin -Resveratrol -Epigallocatechin Gallate (EGCG) |
| Colorectal cancer is a broader term that encompasses both colon and rectal cancer. |
| - | in-vitro, | CRC, | NA |
| 4812- | ASTX, | Astaxanthin suppresses the metastasis of colon cancer by inhibiting the MYC-mediated downregulation of microRNA-29a-3p and microRNA-200a |
| - | in-vitro, | CRC, | HCT116 |
| 2682- | BBR, | Berberine Inhibited Growth and Migration of Human Colon Cancer Cell Lines by Increasing Phosphatase and Tensin and Inhibiting Aquaporins 1, 3 and 5 Expressions |
| - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | HCT116 |
| 5747- | CA, | Caffeic Acid Enhances Anticancer Drug-induced Apoptosis in Acid-adapted HCT116 Colon Cancer Cells |
| - | in-vitro, | CRC, | NA |
| 6160- | Cin, | Cinnamaldehyde induces apoptosis and enhances anti-colorectal cancer activity via covalent binding to HSPD1 |
| - | vitro+vivo, | CRC, | HCT116 |
| 6142- | Cin, | Cinnamaldehyde affects the biological behavior of human colorectal cancer cells and induces apoptosis via inhibition of the PI3K/Akt signaling pathway |
| - | in-vitro, | CRC, | LoVo | - | in-vitro, | CRC, | SW48 | - | in-vitro, | CRC, | HCT116 |
| 5223- | EMD, | Emodin inhibits colon cancer by altering BCL-2 family proteins and cell survival pathways |
| - | in-vitro, | CRC, | DLD1 | - | in-vitro, | Nor, | CCD841 |
| 2521- | H2, | Oxyhydrogen Gas: A Promising Therapeutic Approach for Lung, Breast and Colorectal Cancer |
| - | Review, | CRC, | NA | - | Review, | Lung, | NA | - | Review, | BC, | NA |
| 1678- | PBG, | 5-FU, | sericin, | In vitro and in vivo anti-colorectal cancer effect of the newly synthesized sericin/propolis/fluorouracil nanoplatform through modulation of PI3K/AKT/mTOR pathway |
| - | in-vitro, | CRC, | Caco-2 | - | in-vivo, | NA, | NA |
| 4787- | QC, | Quercetin: A Phytochemical with Pro-Apoptotic Effects in Colon Cancer Cells |
| - | Review, | CRC, | NA |
| - | in-vivo, | CRC, | Caco-2 | - | vitro+vivo, | CRC, | CX-1 |
| 1019- | TQ, | Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation |
| - | vitro+vivo, | CRC, | LoVo |
| 3397- | TQ, | Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer |
| - | Review, | CRC, | NA |
| 3431- | TQ, | PI3K-AKT Pathway Modulation by Thymoquinone Limits Tumor Growth and Glycolytic Metabolism in Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW48 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:6 Cells:% prod#:% Target#:252 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid